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The epidemic of Neonatal 
Abstinence Syndrome, Historical 
References of its’ Origins, 
Assessment, and Management
Enrique Gomez-Pomar1* and Loretta P. Finnegan2
1 Division of Neonatology, Department of Pediatrics, University of Kentucky, Lexington, KY, United States, 2 The College on 
Problems of Drug Dependence, Inc., Philadelphia, PA, United States
Neonatal abstinence syndrome (NAS) refers to a constellation of signs that are present in 
some newborn infants resulting from the abrupt cessation of passive transfer of maternal 
opioids used during pregnancy. The classic NAS refers to infants born to mothers who 
used opioids during pregnancy, but the term has broadened to include infants whose 
mothers have used or abused other psychoactive substances during pregnancy that 
contribute to the expression of the syndrome. Pregnant women who use opioids do 
so illicitly, and/or as medically prescribed for pain relief, and/or as medication assisted 
treatment for opioid dependence. The first case of NAS in infants and the subsequent 
treatment (or lack thereof) was reported in 1875 and was called Congenital Morphinism. 
By 2012, the incidence of NAS increased to more than 30 per 1,000 hospital live births, 
along with an increase in the number of infants being treated pharmacologically for 
NAS, resulting in an increase in the length of stay and healthcare expenses. We present 
historical references on NAS, the various factors and events that led to its increasing 
prevalence and today’s current epidemic. We also review the current tools to assess 
infants with NAS and treatment options in its management.
Keywords: drug withdrawal, neonatal abstinence syndrome, neonate, opioid, methadone, buprenorphine
“The one who does not remember history is bound to live through it again.” [Georges 
Santayana, Spain (1863–1952)]
THe eARLY DAYS OF IN UTERO eXPOSURe TO OPiOiDS
The first description of opium use goes back 6,000 years; then known as “the plant of joy” (1) being 
first isolated by Sumerians around 2,000 years BC (2). Initially used to cause euphoria (probably as 
part of religious rituals), it was found that it could also be used to help people die painlessly and to 
calm crying children (1, 2). Medical use of opium included treatment of a variety of illnesses such as: 
pain (headaches, menstrual cramps, etc.), respiratory (bronchitis, asthma, cough), infections (fever, 
leprosy), and mental problems (melancholy) (1). As opium use spread throughout Europe, China 
and India, its abuse and addiction appeared and advanced but it wasn’t until 1803, after the isolation 
of its main component, morphine, and the expansion of its medical use, that addiction became a 
public health problem (1, 2).
Morphine was marketed by Merck & Co., Inc. in 1827 to be used for pain relief and alcoholism 
treatment (3). In 1853, morphine became the first drug to be used intravenously for pain control 
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during minor surgeries (1, 2). However, morphine was found to 
be as addictive as opium, and efforts were made to synthetize an 
opium derivative that did not cause addiction. The assumption was 
that if potency was high, less quantity should be needed resulting 
in less addiction (2, 3). This effort resulted in the development 
of heroin by Heinrich Dreser in 1898, a drug five times more 
potent than morphine (1, 2). Heroin was distributed by Bayer 
(2) AG (1898–1910) as an over-the-counter medication to treat 
colds, sore throats, pneumonia, and tuberculosis (1). Secondary 
to the belief that heroin was not addictive, it was also proposed as 
treatment for morphine-addicted patients.
The introduction of opium in the US started between 1850 and 
1870 with the arrival of Chinese citizens during the California 
Gold Rush (1–3). Its use rapidly extended to all American major 
cities (1). From 1900 to 1924, heroin was distributed in the US as 
an over-the-counter medication for the treatment of colds and 
the flu and was marketed as safe to be given to pregnant women 
and infants (1). Opium was initially consumed using smoking 
devices, but because of the poor reputation of smokers (most likely 
Chinese laborers and white criminals), consumption spread to the 
middle and upper classes mostly after the availability of oral and 
intravenous forms (4). There were about 300,000 opioid addicts 
at the beginning of the twentieth century, and two thirds of those 
consumers were women who started using prescription opioids 
for a variety of illnesses and continued using them afterward 
(3, 4). Opiate abuse was also exacerbated by poor governmental 
control regarding the sale and distribution of narcotics (4).
At first, public perception of opium addicts was much positive 
than that of alcoholics, influencing the widespread use of mor-
phine and heroin (4). However, these attitudes started to change 
at the beginning of the twentieth century, as negative perceptions 
of who addicts were, and how they became addicted, appeared 
(4). Concomitantly, physicians became more aware of the addic-
tive effects of morphine and heroin and its deleterious effects 
on their patients, which resulted in fewer new cases of medical 
addiction (4–7).
The first attempt to regulate opiates in the US came in 1875, 
by the city of San Francisco, who enacted the Opium Den 
Ordinance, which declared public smoking (opium dens) illegal 
(1). Around that time, alarmed physicians raised their voices 
to remind their colleges about the dangers of opiate addiction 
and to challenge the proposed standards of care that used heroin 
for many afflictions including the treatment of addicts (8). This 
prompted the establishment of more controls across the states (7). 
By 1914, the federal government passed the Harrison Narcotic 
Act (4, 7) which required anyone who imported, produced, sold 
or dispensed “narcotics” to register and keep records of their 
operations. The Act also allowed authorities to prosecute unreg-
istered distributors. The Harrison Act was later replaced by the 
1970 Controlled Substances Act (7) which has been enforced by 
the Drug Enforcement Administration since its creation in 1973.
The term opioid was introduced in the late 1950s to refer to the 
synthetic narcotics (1). Oxycodone is a semisynthetic opioid syn-
thesized from thebaine, an opioid alkaloid found in the Persian 
poppy, and one of the many alkaloids found in the opium poppy 
(9). Oxycodone was initially synthetized in 1916 in Germany and 
used for pain control, especially during World War II. In the post 
war time, and after the negative image of heroin, oxycodone was 
introduced in the US. It has since become one of the best sell-
ing prescription drugs in the country (1). By 1939, meperidine, 
the first synthetic opioid, was created; this was followed by the 
synthesis of methadone in 1946 (2, 10). Due to a nationwide effort 
to create treatment programs for opiate addiction, methadone 
was first used as a maintenance medication in the 1950s (10). 
Buprenorphine was discovered in 1966 and found to be beneficial 
for the treatment of opioid dependence as well as methadone 
(10, 11). Buprenorphine use was approved by the Food and Drug 
Administration in 1985. However, physicians were not permit-
ted to prescribe buprenorphine in treatment settings other than 
Opioid Treatment Programs until the Drug Addiction Treatment 
Act of 2000 (part of the Children’s Health Act of 2000) (10–12).
The use of opioids for pain control in terminally ill patients 
started in 1948 after Cicely Saunders founded the Hospice Care 
movement in London (13). Ms. Saunders introduced the concept 
of a pain-free dignified death using opioids to prevent pain instead 
of using them as treatment. This movement was adopted by the 
US and, in 1984, the Compassionate Pain Relief Act was passed 
allowing physicians to legally treat terminally ill patients with 
heroin (1). However, in 1986 a new call was made to use chronic 
opioid treatment for non-malignant pain, based on the incorrect 
assumption that opioids can be used chronically without causing 
serious addiction (14, 15).
iNADeQUATe PReSCRiBiNG PRACTiCeS 
LeADiNG TO A NATiONAL ePiDeMiC
Opioid prescriptions shifted to the treatment of chronic pain 
resulting in a steep increase in the abuse of prescribed opioids 
with a reported 259 million prescriptions for opioid medications 
in 2012 (16, 17). Approximately half of all emergency room visits 
related to drug misuse in 2011 are related to nonmedical use 
of prescription drugs, 40% of these visits related to opioid pain 
relievers (18). Therefore, treatment admissions have more than 
quadrupled between 2002 and 2012, along with deaths related to 
overdose (11). In 2014, there were almost 19,000 deaths related 
to the overdose of prescription opioids (19). As of 2015, there are 
an estimated two million people living in the US with a substance 
abuse disorder related to prescribed opioids (11).
However, due to stricter controls on prescribed opioids (18), 
there has been a shift to heroin and other options easier to find 
(11, 20). Evidence also shows that individuals who abuse opioids 
orally, will eventually switch to injection routes thus result-
ing in additional health risks related to the injections (20–23). 
Admissions for prescribed opioid abuse decreased from 2004 to 
2013, meanwhile, there was an increase in the number of indi-
viduals using injection and smoking/inhalation methods (21). In 
2015, there were an estimated 591,000 people with heroin use 
disorder and approximately 13,000 deaths related to overdose 
(11); more than five times the number in 2002 (22).
Children and adolescents have not escaped this epidemic; 
from 1997 to 2012 more than 22,000 children were treated for 
opioid poisoning (16). Those among the ages 0–5 years experi-
enced the largest number of exposures to opioids, mostly from 
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unintentional sources (accidental ingestion or therapeutic error) 
(16). However, among teenagers the majority of opioid exposure 
was intentional, being more significant among boys (16). A 
survey from 2015 found that 1 in 23 high school seniors reported 
misusing opiates (18) and research has also shown that teens and 
adolescents who abuse prescription medications are also more 
likely to use other drugs (18).
Sex differences related to substance abuse, like cause of con-
sumption and drug metabolism, make women a unique group 
(24). As described earlier, opioid consumption was already com-
mon among women during the nineteenth century (4), possibly 
relating to women being more likely to suffer from chronic pain 
and being more susceptible to craving and relapse (24). Drug 
abuse and deaths due to overdose are more common in men; 
however, the rate of overdose is increasing more sharply in women 
compared to men (18). Misuse of prescription drugs is also more 
common among men, except in adolescents; adolescent girls, age 
12–17, surpass boys in the use of nonmedical prescription drugs 
(18). Deaths related to overdose of prescription pain relievers are 
also increased more rapidly in women compared to men; reach-
ing an overwhelming 18 women dying per day due to overdose 
in 2010 (24).
Opioids use during pregnancy results in complications to the 
newborn known as neonatal abstinence syndrome (NAS) (25–29). 
From 1995 to 2009, opioid prescriptions for pain management 
in pregnant women doubled (11). In a cohort of more than 
100,000 pregnant women exposed to opioids, nearly 96% were 
non-maintenance prescriptions (30). Women who are pregnant 
or have young children may not look for addiction treatments 
or drop off from treatment due to the fear of legal repercussions 
or that they will be seen as unable to take care of their children 
(12, 24, 31). Stopping opioids during pregnancy is not an option 
as it is associated with poor neonatal outcomes and may result in 
fetal demise (11, 31).
Currently, there is no federally approved medication treat-
ment for pregnant women with an opioid disorder; however, 
methadone and buprenorphine (category C drugs as per the Food 
and Drug Administration) appear to be effective and safe options 
during pregnancy (24, 31). Still, knowledge gaps persist concern-
ing methadone pharmacodynamics, pharmacokinetics and the 
lack of guidelines for adequate dosing during pregnancy (12).
NeONATAL ABSTiNeNCe SYNDROMe
Prior to 1875, infants born to women who were opioid depend-
ent were thought to be unaffected because morphine use among 
women was associated with sterility and loss of sexual desire 
(32). However, in 1875 several cases of deceased infants born 
from mothers dependent on morphine were reported (3, 33, 
34). This condition was called Congenital Morphinism and it 
was described in full term infants who appeared normal at birth 
then began crying inconsolably on the third day of life; some 
of these infants were reported to develop generalized seizures 
(32, 33). Due to a lack of knowledge of the cause of these signs, 
NAS was frequently fatal to newborns (3, 33, 34). As early as 1901, 
it was recognized that this was the result of the infant withdrawing 
from the cessation of the passive transfer of maternal morphine 
and that providing the infant with medication would ease his/
her signs (33, 34). Later on, infants were given opium in small 
quantities to treat their symptoms with reports of success (34).
Due to the low-molecular-weight and lipid solubility of 
opioids, they pass freely through the placenta and to the infant 
(25–27). Fetuses of mothers using opioids and receiving no or 
inadequate prenatal care have an increased risk of having preterm 
birth, intrauterine growth restriction, and an increase incidence 
of fetal demise (26, 31, 35, 36). Several drugs have been identified 
to cause some signs of withdrawal in the infant, but the most 
common cause is in utero opioid exposure (3, 25–27, 37–40). The 
cutting of the umbilical cord causes an abrupt termination of the 
supply of opioids to the infant and increases the risk of developing 
NAS (25–27).
Clinically recognizable abstinence signs appear in 60–80% of 
opioid-exposed neonates. Their spectrum of signs is affected by 
variables such as the total fetal exposure, the amount and purity of 
the drugs taken by the mother, length of use, maternal and infant 
drug metabolism, and the individual kinetics of placental drug 
transfer (25–27, 38, 40). Genetic and epigenetic factors play an 
important role in the incidence and severity of NAS in neonates 
(41, 42). Timing of presentation of NAS is usually within the first 
72 h of life but it can occur as late as 7 days of life (27, 38). Signs 
of NAS can be classified in: (a) neurologic manifestations due to 
increased excitability, including tremors, excessive and/or high 
pitch cry, hyperactive Moro, increased muscle tone, seizures; (b) 
gastrointestinal manifestations include diarrhea, vomiting, unco-
ordinated sucking, and swallowing; and (c) autonomic manifes-
tations include fever, sweating, nasal stuffiness, and increased 
respiratory rate (25, 27, 37, 40, 43, 44). The most common signs 
are related to the neurologic and gastrointestinal manifestations, 
however, there is variability in the presentation of signs among 
neonates (27, 38, 40, 45).
Opioid excretion in breastmilk was recognized as early as 1901 
(34). Breastfeeding was encouraged in these infants as it helped 
“calm them” and in some occasions ease their symptoms without 
pharmacological intervention (34, 46). Evidence has shown that 
mothers on methadone or buprenorphine have low, safe levels of 
the medication in their breast milk (47). Therefore, the current 
recommendation is to encourage breastfeeding in those infants 
whose mothers are on a supervised opioid maintenance program, 
are compliant and not using street drugs (27). Breastfeeding of 
these infants has demonstrated to be beneficial in decreasing 
their NAS signs and hospital stay and improving maternal–infant 
attachment most probably due to the soothing effect of breast-
feeding (27, 47, 48).
AN OBJeCTive evALUATiON OF iNFANTS 
wiTH NAS
Assessment and diagnosis of NAS starts with clinical suspicion 
based on maternal history (27, 32, 49). In order to provide an 
objective way to identify and categorize infants with NAS, several 
scoring systems were proposed (50), including the Finnegan 
Neonatal Abstinence Scoring System (FNASS) (25, 37), the Lipsitz 
tool (51), the Neonatal Narcotic Withdrawal Index (52), and the 
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Ostrea tool (35). Currently, the FNASS is the most commonly 
used scale (25, 27, 37, 53–56).
The FNASS was developed in 1975 using a clinimetric 
approach based on the most common signs of infants with NAS 
(25, 37, 57). The FNASS consists of 21 items, was analyzed for 
interuser reliability [mean interrater reliability coefficient of 0.82 
(0.75–0.96)] and validated for the diagnosis of NAS (26, 58). 
The FNASS provides cutoff points (3 continuous scores ≥ 8 or 2 
continuous scores ≥ 12) for the identification of the infants that 
may require pharmacological treatment and pharmacological 
guidelines for the treatment of infants with NAS (25, 37, 59). 
Subsequent analysis of the external factors that may influence 
the FNASS showed that it is an objective and reliable tool for the 
diagnoses and management of infants with NAS (60).
The Lipsitz tool was developed around the same time of the 
FNASS (1975) (51). It contains 11 items with scores from 0 to 3 
and proposes to evaluate infants twice per day 90 min prior to 
feeds. It found sensitivity of 77% using scores ≥ 4 as an indica-
tion of withdrawal signs. Other scales like the Neonatal Narcotic 
Withdrawal Index (7 category scale that proposes a cutoff of 5 
obtained twice during a 24-h period) (52) and the Ostrea tool 
(a six criteria scale) (35) were proposed; however, these scales did 
not gain much popularity in clinical settings.
The FNASS is a comprehensive and lengthy tool so there have 
been several attempts to modify it (40). The Neonatal Withdrawal 
Inventory (61) proposed an 8–point checklist that was derived 
from the FNASS. The investigators reported on inter-rater reli-
ability, sensitivity and specificity using the same cutoff points as 
the FNASS; however, the scoring system was not validated. The 
FNASS-short form developed by Maguire et al (62) proposed a 
7-point checklist using the same cutoff value as the FNASS. The 
simplified FNASS (sFNASS) is a 10-point scale that was statisti-
cally derived using the FNASS scores of a database of 185 patients 
(63). This was subsequently validated with a different database of 
182 infants from another NICU with excellent correlation to the 
original FNASS. The sFNASS proposes cutoff values of 6 and 10 
to identify scores of 8 and 12 on the original FNASS. However, a 
prospective evaluation of the sFNASS is needed (63).
The Maternal Opioid Treatment: Human Experimental 
Research (MOTHER) project developed a score by modifying the 
FNASS (64). The MOTHER NAS scale is a 19 item scoring system 
developed by adding (failure to thrive and irritability), removing 
(myoclonic jerks, mottling, nasal flaring and excessive sucking), 
or modifying the scores in the items of the original FNASS (65). 
Infants were evaluated twice daily and pharmacological treatment 
was offered by their proposed guidelines (64). Short screening 
tools based on the MOTHER NAS scale have also been proposed 
(66); however, its validation awaits further studies.
At present, there is no national consensus as to which tool 
to use, the cutoff points for treatment, and the interval between 
assessments (27, 50, 53, 56). A 2006 review by Sarkar et  al. 
found that the FNASS was used by 65% of the 75 units that were 
analyzed, which is consistent with other reports (25, 27, 37, 53– 
56, 67). Conversely, most of the concerns were based in the length 
of the tool and the fact that it was designed for opioid withdrawal 
not for polydrug users. However, the majority of signs that infants 
experience from in utero polydrug exposure concomitantly with 
opioids (benzodiazepines, SSRI, sedatives) are similar and addi-
tive to those seen with opioids alone (27).
An evaluation of the validity of the cutoff points was made 
by Zimmermann et  al. in 2010 (68). They applied the FNASS 
to infants without a history of opioid exposure and found that 
scores ≥8 should be considered pathological (68). Infants without 
opioid exposure commonly have scores <8 and, if a score of 8 is 
found in one evaluation, they subsequently became normal (68). 
This finding validates the suggestion of requiring 3 continuous 
abnormal scores to consider pharmacological treatment. To con-
sider, in the development of the FNASS, 200 babies born without 
drug exposure (including no analgesics for labor and delivery) 
never received a score of ≥8 or higher. Most were in the 1–5 range. 
Current recommendations encourage each nursery to develop a 
protocol that includes a standard assessment tool for infants with 
NAS (27, 32).
MANAGeMeNT OF NAS
Management of infants suffering from NAS has two main compo-
nents, non-pharmacological and pharmacological interventions 
that are used as needed. Non-pharmacological options have been 
used since the early identification of congenital morphinism 
(34, 46). The main components of a non-pharmacological 
approach are recommended to decrease the environmental stim-
uli that the infant is exposed to (minimize environmental stimuli, 
swaddling, rocking) and minimize hunger (demand feedings) 
(32, 69–71). These interventions have demonstrated a decrease 
in the severity of symptoms (32, 50, 69) and new evidence is 
showing that they may be a key component in the management 
of infants with NAS (67, 69).
Recently, a new approach called the Eat, Sleep, Console (ESC) 
model was reported (69). This model is based on intensive non-
pharmacological therapy of infants with NAS, specifically those 
from mothers on methadone. Over a period of 8 years, the inves-
tigators showed a decreased need for pharmacological therapy 
with a shortened hospital stay with the ESC method (when 
comparing a historical comparison group to the post intervention 
group) (69). However, it seems that constant maternal rooming-
in is key to the model, making it difficult to apply nationwide and 
the model is based on a subjective evaluation (without a report of 
other signs of NAS), making it difficult to replicate (69).
Another concern is at which point the non-pharmacological 
interventions alone will have deleterious effects on the neurologi-
cal development of infants with NAS. Infants with antenatal opi-
ate exposure will have an increased noradrenergic activity, among 
other neurological abnormalities, once they are born and the opi-
ate supply ceases (32, 43, 72, 73). Therefore, we question that not 
offering pharmacological treatment is enough for these infants 
and could be detrimental in the long term. Further research is 
necessary to evaluate the long term effects of the ESC model.
At present, infants diagnosed with NAS that are in need of a 
pharmacological treatment are managed in a neonatal intensive 
care unit (NICU) (28, 74). An infant with NAS admitted to the 
NICU will have difficult access to rooming-in and a low stimuli 
environment. Holmes et  al. reported a program in which 207 
infants were treated in a pediatric unit instead of a NICU (74). 
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This allowed constant rooming-in and resulted in decreased of 
use of pharmacological treatments, length of stay and overall 
health cost in an overall safe environment to the infant (74).
Initially, when NAS (Congenital Morphinism) was identified, 
no pharmacological treatment was given and these infants died, 
not only from the lack of treatment for NAS but, in some, from 
prematurity (3, 33, 34). Once the condition was recognized to 
be caused by the interruption of the placental supply of opi-
ates, pharmacological interventions were provided resulting in 
improvement of the survival rates (33, 34). Initially, infants were 
treated with opium, paregoric and oral diluted morphine (34). 
Currently, the most common medications used in US nurseries 
include morphine and methadone with phenobarbital, clonidine, 
and buprenorphine being used alone or as adjuvant therapy. 
However, pharmacological management is not standardized; 
therefore, medication dosing and weaning varies center to center 
(27, 53, 55, 56, 75, 76). The threshold as to when an infant needs 
pharmacological intervention is questioned by some clinicians 
and, if treated, the choice of which medication to use remains 
controversial (27, 50, 53, 56, 67, 77–79).
Morphine and methadone have been the drugs of choice to 
treat infants where maternal opioid exposure is demonstrated 
and NAS is established (50, 53, 64). Morphine is given orally, 
typically every 3–4 h at 0.05‒0.2 mg/kg/dose (50, 80). If the infant 
does not improve with the initial dose of medication, it can be 
increased to obtain the desired effect. Morphine can be weaned 
every 24–48 h (50, 80).
Methadone is also given orally every 4–12  h, titrated in a 
range of 0.05‒0.1 mg/kg/dose, and then weaned over time (50). 
However, the use of methadone is controversial due to its long 
half-life and prolonged excretion rate that could require longer 
hospitalization (65, 79).
Clonidine, a non-opioid α2-adrenergic receptor agonist, has 
been recommended as a safe alternative for single-drug therapy 
of infants with NAS (72). Clonidine eases the signs and does 
not include the narcotic effects of opioids (80). Clonidine can 
be initially started at 0.5‒1  μg/kg, followed by 0.5‒1.25  μg/kg 
per dose q 3 h with proposed increments of 25% of the initial 
dose and weaning by 10% of the maximum dose every 48 h (50). 
A potential side effect is blood pressure fluctuations; however, 
no studies have reported this side effect at the doses used for the 
treatment of infants with NAS (72, 80). Clonidine also can be 
used as adjuvant medication when opioids were initially used.
Phenobarbital, a γ-amino butyric acid agonist with sedative 
and anticonvulsant properties, has been used for years for the 
treatment of NAS (70). However, phenobarbital is most commonly 
used as an adjuvant therapy and not as a single-drug medication 
(32, 80). Phenobarbital requires a loading dose of 5  mg/kg IV, 
IM, or PO and a maintenance dose of 3–5 mg/kg divided into 
three doses (every 8 h). Another approach is a loading dose of 
20 mg/kg with a maintenance dose of 2–6 mg/kg day to achieve 
plasma level concentrations between 20 and 30 μg/mL (80, 81). 
Once the infant is controlled, phenobarbital can be weaned by 
15% of the daily dose until the medication is discontinued (80).
Treatment of NAS must take into consideration factors that 
have been shown to enhance the expression of NAS and effect the 
response of infants to non-pharmacological and pharmacological 
interventions. These include neonatal (41, 42) (gestational age, 
neonatal metabolism, genetic predisposition, and epigenetics), 
maternal (12, 30, 38) (smoking, type, length, quality, and quantity 
of the used drug, SSRI use and the enrollment in Medication 
Assisted Therapy), and external factors (69) (decision to breast-
feed and rooming-in possibility). Significant variability still 
persists regarding pharmacological treatment of infants with 
NAS (dose initiation, increments, and weaning). Therefore, each 
unit needs to develop a protocol to provide consistent treatment 
to the affected infants (27, 50).
NAS AS A NATiONAL ePiDeMiC
The incidence of NAS has steadily increased since the 1970s and 
has now become a significant public health problem (30, 37). 
NICU admissions due to NAS have increased from 7 cases/1,000 
admissions in 2004 to 27 cases/1,000 admissions in 2013 with 
an increase in the median length of stay for infants with NAS 
from 13 to 19 days (28). The proportion of infants who received 
pharmacotherapy also increased, 74% in 2004–2005 to 87% in 
2012–2013, resulting in a 35% increase in hospital costs (28).
Prescribed opioids are prevalent among mothers of infants with 
NAS. A cohort of more than 10,000 infants with NAS showed that 
methadone, opioid pain relievers and buprenorphine was used in 
31, 24, and 15% of the mothers, respectively (28). Pregnant women 
tend to use less illicit drugs and smoking compared to non-pregnant 
women, excluding the group age between 15 and 17 years old (27). 
However, heroin use in developed countries is increasing (32); dur-
ing the period of 2000–2012, NAS associated with use of heroin 
or an opioid prescription increased by fivefold (18). Mothers who 
abuse heroin are usually unmarried, unemployed, less educated 
and less insured; which usually implies that the pregnancies are 
unplanned and have minimal, if any, prenatal care (32).
State differences are noted when analyzing the incidence of 
NAS. A CDC report that included 28 states found an overall 
incidence of 6 cases per 1,000 hospital births in 2013 (82). This 
report also shows a wide difference among states (0.7 per 1,000 
vs. 33.4 per 1,000 in Hawaii and West Virginia, respectively) (82). 
These differences can be attributed to opioid prescribing policies, 
prevalence of illicit opioid use, or using a different diagnostic 
code to classify the disease. Variations among states must be 
taken into consideration when designing public health policies 
for the prevention of NAS.
Strategies to decrease the incidence of NAS must start during 
the preconception period with an adequate planning and an hon-
est discussion of how long-term opioid use affects the pregnancy 
and the infant (31, 82). Prescribed opioids during pregnancy is still 
one of the most common causes of NAS and should be carefully 
considered for each case (30). All states should have a prescrip-
tion drug monitoring program, which has been demonstrated to 
be satisfactory in reducing inadequate prescribing and overdose 
deaths (82). Early identification of pregnant women who use 
illicit drugs is vital in order to improve outcomes (31), however, 
pregnant women need to have access to comprehensive, fear free 
treatment options that include medication-assisted treatment, 
prenatal care and psychosocial support with an honest discussion 
about the infant’s future (31).
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CONCLUSiON
A national effort is needed to improve maternal health in the 
prenatal period and to standardize the assessment and manage-
ment of their infants with NAS (3, 27, 32, 65). Research strategies 
need to take into consideration that a large number of mothers are 
not in a supervised maintenance program and are polydrug users 
(27, 39). Assessment of infants with NAS needs to be standard-
ized (32) and the chosen assessment tool needs to have strong 
clinimetrics (57) rather than psychometric properties (83). Non-
pharmacological approaches need to be offered to all mothers and 
infants that are affected (32, 69, 84). Infants diagnosed with NAS 
should be managed, when possible, in a setting where constant 
rooming-in is available (69, 74).
Recommendations for the pharmacological treatment of 
NAS, when indicated, need to come from randomized clinical 
trials with regard to which treatment to initially provide, how 
to escalate the dose and how to wean the medication(s), tak-
ing into consideration the safest time to be discharged home 
(32, 49). The current lack of education of the many disciplines 
involved in the assessment and treatment of drug dependence 
during pregnancy and NAS, makes it difficult for clinicians 
and researchers to approach this epidemic and to avoid the 
potential detrimental consequences to this maternal/infant dyad 
(27, 31, 69, 85). Clinicians, researches, and government funding 
agencies need to combine their expertise to provide adequate 
education and treatment protocols for drug dependent pregnant 
women and their infants with NAS. Without this, they will not 
live a full and healthy life due to this chronic relapsing disease 
with the potential to increase the intergenerational transmission 
of drug dependence and potentiate the epidemic.
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